An evidence-based guide to rare and atypical tendinopathy presentations, including fluoroquinolone-induced tendinopathy, calcific variants, systemic disease associations, and bilateral spontaneous ruptures. prepared by the HealthRX.com Editorial Team.
A clinical deep-dive into the rare and atypical presentations of type 2 diabetes, including euglycemic DKA, latent autoimmune diabetes in adults, ketosis-prone T2D, and more. Includes statistics, guideline quotes, and original frameworks.
The Farxiga label describes no withdrawal syndrome, but urinary glucose loss persists about 3 days after stopping. It also advises a pre-surgery hold.
A guide to how dapagliflozin (Farxiga) affects sexual function in men and women with type 2 diabetes, heart failure, and CKD, including trial data, mechanistic explanations, and clinical management of genital mycotic infections.
Does Prolia (denosumab) affect appetite or cravings? A clinician-level review of the FREEDOM trial data, FDA adverse-event records, RANK/RANKL biology, and practical management steps for patients on denosumab.
MD/PharmD-level guidance on managing denosumab injection timing during travel, timezone shifts, and international trips. Covers the 6-month dosing window, cold-chain requirements, and what to do if your Prolia shot is delayed.
A deep dive into how testosterone replacement therapy changes liver glucose output, insulin sensitivity, and cardiometabolic risk markers, with trial data and dosing context.
Hormonal shifts, muscle loss, and metabolic slowdown all converge in midlife to make weight loss genuinely harder. A HealthRX.com clinical breakdown of the mechanisms and evidence-based strategies that actually work.
Menopause does not directly cause type 2 diabetes, but the hormonal shifts it triggers, falling estrogen, rising visceral fat, worsening insulin resistance, meaningfully raise a woman's risk. Learn what the evidence shows, which women are most at risk, and what you can do about it.
A guide to dulaglutide (Trulicity) safety in adults aged 50, 64, covering cardiovascular outcomes, GI tolerability, hypoglycemia risk, polypharmacy, and the REWIND trial data.
Why dulaglutide (Trulicity) stops working and what to do about it. MD-level plateau troubleshooting covering dose optimization, GLP-1 receptor tachyphylaxis, combination strategies, and switch protocols backed by primary trial data.
A guide to dulaglutide (Trulicity) safety for young adults ages 18, 29, covering trial evidence, side effects, fertility, contraception, and dosing guidance with primary-source citations.
Evidence-based guidance on how long to hold dulaglutide (Trulicity) before surgery, why delayed gastric emptying raises aspiration risk, and how to manage blood glucose in the perioperative period.
A deep dive into how dutasteride (Avodart) is metabolized, how it affects androgen-driven thermogenesis, and what clinicians and patients need to know about energy expenditure changes on long-term therapy.
A clinical guide to dutasteride (Avodart) use after bariatric surgery, covering altered pharmacokinetics, absorption concerns, dosing strategies, and hair-loss treatment evidence in post-bariatric patients.
An evidence-based look at dutasteride (Avodart) and cognitive function, covering neurosteroid pathways, clinical trial data, risk stratification, and what patients should discuss with their prescribers.
A clinical review of empagliflozin (Jardiance) and its effects on mental health, mood, depression, anxiety, and cognitive function. Covers EMPA-REG OUTCOME, DKA risk, and practical guidance for patients and prescribers.
EMPA-KIDNEY found a 28% reduction in kidney/CV risk with Jardiance. Learn why eGFR dips at first, who benefits, and FDA contraindications.
Evidence-based dosing guide for enclomiphene citrate in men aged 30-49 with secondary hypogonadism. Covers starting doses, titration, monitoring, and clinical trial data.
A clinician-level review of enclomiphene citrate's cardiovascular effects in men with secondary hypogonadism, covering lipid profiles, blood pressure, erythrocytosis risk, and how it compares to exogenous testosterone therapy.
A guide to enclomiphene citrate dosing in the 50, 64 age group, covering starting doses, titration, monitoring labs, cardiovascular considerations, and how older-adult physiology changes the risk-benefit calculation.
A guide to how enclomiphene citrate affects libido, erectile function, and sperm production in men with secondary hypogonadism, with primary-literature citations and dosing context.
A guide to enclomiphene citrate safety for men aged 18, 29, covering testosterone restoration, fertility preservation, adverse effects, monitoring protocols, and current guideline positions.
A clinical review of epitalon tetrapeptide and its effects on kidney function, including renal protection mechanisms, potential risks, and what current evidence means for patients and prescribers.
A guide to oral estradiol tablet dosing for adults aged 30 to 49, covering starting doses, titration, progestogen co-therapy, safety monitoring, and where the evidence is solid versus where individualized judgment is required.
A guide to oral estradiol safety for adults aged 30 to 49, covering cardiovascular risk, clot risk, breast cancer data, dosing, monitoring, and when transdermal estradiol is the better route.
A clinician-level review of oral estradiol use in patients with autoimmune conditions, covering disease-specific risks, pharmacokinetics, guideline positions, and practical prescribing decisions.
A clinical guide to oral estradiol dosing in the 50, 64 age group, covering starting doses, titration, cardiovascular risk stratification, WHI trial context, and current guideline recommendations.
A clinically detailed review of oral estradiol safety for adults ages 50 to 64, covering cardiovascular risk, VTE, breast cancer, bone effects, drug interactions, and how the timing hypothesis reshapes prescribing decisions in this age group.
A clinician-level guide to switching oral estradiol to or from transdermal, vaginal, and injectable estrogen formulations, with dosing equivalencies, symptom-bridging protocols, and safety checkpoints backed by primary trial data.
A clinical guide to adjusting oral estradiol dosing schedules during long-haul travel, timezone crossings, and schedule disruptions. Covers PK rationale, practical timing windows, and when to contact your prescriber.
A GRADE-graded review of the clinical evidence for estradiol transdermal patches: vasomotor symptom relief, cardiovascular safety, bone protection, breast cancer risk, and route-of-administration differences. MD/PharmD-level depth with primary-literature citations.
A week-by-week guide to your first month on the estradiol transdermal patch, covering symptom timelines, serum levels, side-effect windows, and when to call your prescriber.
A guide to how transdermal estradiol affects hair growth, hair loss, skin thickness, collagen, and wound healing, with primary-literature citations and clinical dosing guidance.
A clinician-level review of how transdermal estradiol affects depression, anxiety, cognition, and mood across perimenopause and postmenopause, with primary-literature citations and prescribing guidance.
Why your estradiol patch stops working, what labs to check, how to adjust dose or delivery, and when to switch to a different HRT formulation. MD/PharmD-level guidance with primary literature.
Evidence-based guidance on when and how to restart transdermal estradiol after acute illness, including timing, dose considerations, thrombosis risk, and monitoring. Written for patients and pending qualified physician review.
Evidence-based guidance on when and how to pause estradiol transdermal therapy before surgery, including VTE risk data, anesthesia interactions, and restart protocols.
A physician-level review of how transdermal estradiol affects sexual function in postmenopausal women, covering libido, vaginal health, dyspareunia, and key trial data including the WHI Estrogen-Alone study.
A guide to estradiol transdermal monitoring in women aged 18, 29, covering lab schedules, symptom tracking, fertility planning, and safety benchmarks.
When should you stop Lunesta (eszopiclone) before surgery? Learn the evidence-based hold window, drug interactions, CNS depression risks, and what to tell your anesthesia team.
A clinical review of alprostadil pharmacogenomics, dosing adjustments, and safety considerations specific to East Asian patients, including CYP enzyme variation, BMI thresholds, and ethnicity-stratified trial data.
A guide to AndroGel pharmacogenomics, dosing thresholds, and safety considerations specific to East Asian patients, with cited trial data and pharmacogenomic references.
A clinical review of BPC-157 dosing for Hispanic and Latino patients, covering pharmacogenomics, diabetes-related considerations, CYP variant data, and practical prescribing guidance prepared by the HealthRX.com Editorial Team.
A detailed clinical review of enclomiphene citrate safety, pharmacogenomics, and dosing considerations specific to Black and African ancestry patients, including G6PD prevalence, cardiovascular risk, CKD overlap, and ethnicity-stratified evidence.
A clinical review of GHK-Cu (copper tripeptide) efficacy differences in East Asian patients, covering pharmacogenomics, ethnicity-stratified data, dosing considerations, and what providers need to know before prescribing.
A clinical deep-dive into how GHK-Cu (copper tripeptide) may behave differently in South Asian patients, covering pharmacogenomics, copper metabolism, dosing considerations, and ethnicity-specific safety signals.
No trial cited compares NMN or NR response by ancestry. This page reviews Japanese NMN trials, ALDH2 rs671, trial doses and US status.
A guide to oral minoxidil dosing for South Asian patients, covering cardiovascular risk, pharmacogenomics, ethnicity-stratified data, and practical starting doses.
A clinician-focused review of semaglutide 0.5 to 2.0 mg efficacy differences in Hispanic and Latino patients, covering ethnicity-stratified RCT subgroup data, pharmacogenomics, insulin resistance phenotypes, and dosing considerations.
What the Prometrium label and PEPI trials report about Hispanic and Latino patients, including dosing, trial population and variability in blood levels.
A clinician-grade review of sermorelin acetate pharmacogenomics, pharmacokinetics, and dose-adjustment considerations specific to patients of Black or African ancestry, with cited trial data and practical guidance.
A clinical review of sermorelin acetate pharmacogenomics, GH-axis physiology, and race-stratified evidence relevant to Black and African ancestry patients, including dosing considerations and documented efficacy gaps.
What the Aldactone label says about race and ethnicity, the SAFA acne trial results, dosing by indication and potassium monitoring for spironolactone.
A guide to tadalafil pharmacogenomics, dosing, and safety considerations specific to patients of Black or African ancestry, with ethnicity-stratified data, guideline citations, and practical prescribing guidance.
This page reviews what Egrifta trials and labels report for tesamorelin. No ancestry-specific results or dose adjustments are given.
A clinical evidence review of how East Asian pharmacogenomics, body-composition norms, and androgen-receptor biology may affect testosterone cypionate dosing, monitoring, and safety discussions, with an explicit map of what is established versus extrapolated.
What the Renova tretinoin label says about darker skin, irritation, pigmentation reports and sun protection, and where South Asian data are missing.
A clinical deep-dive into vaginal estradiol pharmacogenomics, ethnicity-stratified trial data, and practical dose-adjustment considerations for Black and African ancestry patients, prepared by the HealthRX.com Editorial Team.
Evidence-based guidance on vardenafil dosing for South Asian men, covering CYP3A4/CYP3A5 pharmacogenomics, elevated CV risk at lower BMI, drug interactions with metformin and statins, and practical starting-dose recommendations.